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Abstract
Background Dietary flavonols may play an important role in the
adjunct therapy of chronic inflammation. The availability of
therapeutic formulations of pentahydroxyflavone glycoside,
rutoside (RU), led us to investigate the ability of this molecule to
modulate the release of various proinflammatory mediators from
human activated macrophages in vitro and to ameliorate arthritic
markers in a rat model.
Methods RU was added simultaneously to human
macrophages during their activation. Cells were then analyzed
for inflammation-related gene expression using a specific array,
and cell supernatants were collected to measure inflammatory
mediators. RU was also injected into adjuvant-induced arthritic
rats, and disease progression and body weight were evaluated
until 50 days after injection. Sera and peritoneal macrophages
were also collected to quantify the RU effect on various
inflammatory markers.
Results RU inhibited inflammation-related gene expression in
activated human macrophages and the release of nitric oxide,
tumor necrosis factor-alpha, interleukin (IL)-1, and IL-6 from
these cells. In a rat model, RU inhibited clinical signs of chronic
arthritis, correlating with decreased levels of inflammatory
cytokines detected in rat sera and macrophage supernatants.
Conclusion Thus, RU may have clinical value in reducing
inflammatory manifestations in human arthritis and other
inflammatory diseases.
Introduction
The immune system has evolved to protect the host from
microbial infection. Nevertheless, a breakdown in the immune
system often results in infection, cancer, and autoimmune dis-
eases. Multiple sclerosis, rheumatoid arthritis (RA), type 1 dia-
betes, inflammatory bowel disease, myocarditis, thyroiditis,
uveitis, systemic lupus erythromatosis, and myasthenia gravis
are organ-specific autoimmune diseases that afflict more than
5% of the population worldwide. Although their etiology is not
known and a cure is still wanting, promising data raised in
human RA implied macrophage mediators in disease progres-
sion [1,2]. Macrophages are the major source of inflammatory
mediators during immune response once activated by auto-
antibodies or by antigen-specific Th1 cell-derived lymphokines
[2,3]. Though essential for the elimination of invasive antigens,
chronic expression of the above mediators can induce a vari-
ety of inflammatory disorders, including RA and many other
autoimmune diseases [2]. During RA, patients have an
increased number of monocytes, particularly inflammatory
monocytes, circulating in peripheral blood [4-6] and have an
elevated number of macrophages in the joints [5]. These cells
are highly activated and are one of the main producers of
interleukin (IL)-1β and tumor necrosis factor-alpha (TNF-α),
two essential proinflammatory cytokines required for the pro-
AIA = adjuvant-induced arthritis; AP-1 = activation protein-1; FCS = fetal calf serum; HC = hydrocortisone; IL = interleukin; iNOS = inducible nitric 
oxide synthase; L-NIL = N(6)-(1-iminoethyl)-L-lysine/2HCl; MCP-1 = monocyte chemoattractant protein-1; MIF = macrophage migration inhibitory fac-
tor; NF-κB = nuclear factor-kappa-B; NO = nitric oxide; PBL = peripheral blood-derived mononuclear leukocyte; PBS = phosphate-buffered saline; 
PGE2 = prostaglandin E2; PHA = phytohemagglutinin-P; RA = rheumatoid arthritis; RU = rutoside; s.c. = subcutaneous; TNF-α = tumor necrosis 
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gression of RA because they are capable of inducing other
proinflammatory cytokines and activating matrix metalloprotei-
nases in autocrine and paracrine fashions [2]. Inhibitors of IL-
1 and TNF-α cause a reduction in synovial inflammation, bone
destruction, and macrophage infiltration in patients with RA
[7,8]. A critical role of TNF-α and IL-1 during RA pathogenesis
was confirmed by the recent development of appropriate ther-
apeutic counterstructures [9].
In patients with autoimmune diseases, the use of dietary sup-
plements is on the rise, mainly because they are effective, inex-
pensive, and relatively safe [10]. Recent studies indicate that
two main flavonols, quercetin and its glycosylated form, rutin
(or rutoside, RU), attenuate various inflammatory functions of
macrophages in human or animal models [11-15]. Flavonols
are compounds isolated from various plants that traditionally
have been used for pain and vascular protection [11]. Querce-
tin inhibits inflammatory reactions by regulating the generation
of inflammatory cytokines such as IL-6, TNF-α, and interferon-
gamma and associated activation protein-1 (AP-1) and
nuclear factor-kappa-B (NF-κB) signaling pathways in immune
cells in vitro and in vivo [10,15]. RU has similar in vitro effects
on immune cells but differs from quercetin by its higher thera-
peutic index and the absence of a modulatory effect on the cell
cycle and apoptosis [16,17].
Various RU formulations for systemic use have been commer-
cially available for more than 40 years and are used primarily
as treatment for edema related to venous insufficiency [11].
Oral administration of RU attenuated bowel inflammatory syn-
drome [18] and a variety of other acute and chronic inflamma-
tions in murine models [19,20]. The scavenging property of
rutin led to a decrease of oxygen radical overproduction of leu-
kocytes of patients with RA in vitro [21]. Meanwhile, the exact
anti-inflammatory mechanism(s) of RU and its cellular target(s)
were not elucidated even though a decrease of nitric oxide
(NO) and IL-1β production has recently been suggested in
mice [19].
This led us to investigate the anti-inflammatory potential of RU
on purified human activated macrophages, key effector cells in
inflammatory diseases. Macrophage-related inflammatory
responses were then analyzed at transcriptomic and proteic
levels in vitro in order to clarify the anti-inflammatory effect of
RU in human cells. RU was subsequently tested in vivo at pre-
ventive or postarthritic levels in a rat model of chronic arthritis.
Data point out the inhibitory effect of RU on inflammatory
cytokines, corroborating its ability to significantly reduce clini-
cal signs in arthritic rats.
Materials and methods
Reagents
For  in vitro experiments, 3,3',4',5,7-pentahydroxyflavone-3-
rutinoside trihydrate (RU) (>97% purity powder; Acros Organ-
ics, Noisy-le-grand, France) was used after suspension in dis-
tilled water. For in vivo subcutaneous (s.c.) injections in rats,
RU was suspended in saline.
Human cells
Peripheral blood samples were obtained from healthy volun-
teers with their informed consent after the approval of this
study by the institutional ethics committee. These samples
were pretested for the absence of HIV or hepatitis virus infec-
tions. Peripheral blood-derived mononuclear leukocytes
(PBLs) were obtained by Ficoll gradient separation, and mono-
cytes were subsequently separated from other leukocytes by
adherence to CD14 beads (Miltenyi Biotec, Paris, France).
CD14- PBLs were used for the hematotoxicity test of various
RU preparations. Briefly, cells were incubated in medium alone
or with 10-6 M phytohemagglutinin-P (PHA) (5 μg/mL; Murex
Biotech Ltd, Dartford, UK) in order to induce lymphocyte pro-
liferation. RU was added at different concentrations, cells
were harvested 4 days later, and apoptotic/necrotic versus
total cells were counted as indicated below. CD14+ cells were
then suspended in RPMI 1640 medium supplemented with
100 U/mL penicillin, 100 μg/mL streptomycin, 2 mM
glutamine, and 10% fetal calf serum (FCS) (all from Gibco-
Europe, Paisley, Scotland). The above culture medium, chem-
icals, and FCS were endotoxin-free and tested for the absence
of direct activation effects on human monocytes (CD23
expression and TNF-α production as activation markers). After
these procedures, more than 95% of cells expressed CD14
antigen and displayed cytochemical characteristics of mono-
cytes/macrophages [22].
Experimental arthritis and rats
Female Lewis rats (Janvier, Le Genest St Isle, France) were
housed under standard laboratory conditions with free access
to food and water. The temperature was kept at 22°C ± 2°C,
and a 12-hour light/dark schedule was maintained. The Animal
Research Committee of the Agriculture Ministry approved this
investigation. All animal procedures were performed in strict
accordance with the guidelines issued by the European Eco-
nomic Community (directive 86/609). Adjuvant-induced arthri-
tis (AIA) was obtained in 6-week-old animals by s.c. injection
at the base of the tail of 300 μL (1.8 mg) of inactivated Myco-
bacterium butyricum (Difco Laboratories Inc., now part of Bec-
ton Dickinson and Company, Franklin Lakes, NJ, USA) diluted
in an emulsion of 8 mL of Vaseline oil, 1 mL of polysorbate 80,
and 1 mL of phosphate-buffered saline (PBS) (Laboratoires
Eurobio, Courtaboeuf, France). Rats were boosted 1 week
later with the same dose of antigen and observed for up to 50
days after immunization for clinical signs of chronic arthritis.
Evaluation of AIA severity was performed by two independent
observers with no knowledge of the treatment protocol. The
severity of AIA in each paw was quantified daily by an arbitrary
clinical score measurement from 0 to 2 as follows: no signs of
inflammation (0), swelling alone (0.5) for each paw, immobility
(0.5) for each paw, 2 being the highest score with both paws
swelling and immobile. Weight evolution of the animals wasAvailable online http://arthritis-research.com/content/10/1/R19
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measured daily. Rats were treated with five injections (every 2
days) of RU, saline, or hydrocortisone (HC) (Sigma-Aldrich,
Saint Quentin Fallavier, France) as indicated in the Results
section. Injections were initiated 1 day after the appearance of
the first arthritic symptoms (therapeutic) or on the first day of
immunization (preventive). For macrophage collection, animals
were anaesthetized with ether and the peritoneal cavity was
washed with 10 mL of cold PBS (pH 7.4). After centrifugation
at 300 g for 10 minutes at 4°C, cells were collected, counted,
and adjusted to 106 cells per milliliter with culture medium.
After 96-hour incubation in medium alone, cell supernatants
from disease-free and AIA rats were collected for mediator
quantification. To activate the production of various inflamma-
tory mediators from rat peritoneal macrophages, cells were
incubated with lipopolysaccharide (10 μg/mL; Sigma-Aldrich).
RU was added simultaneously to cell activation. Cells or their
supernatants were then tested for the presence of various
inflammatory mediators.
Human cell activation
Monocytes/macrophages were activated through the physio-
logical CD23 pathway [22]. PBL-derived adherent cells must
be preactivated to express surface CD23 as described [22]
following their incubation with various cytokines, including
recombinant human IL-4 (50 ng/mL), during 24 hours at 37°C.
After washing, cells were tested for their surface CD23
expression (>80% CD23+) and then incubated in the pres-
ence of crosslinking CD23-MAb (clones 135, IgG1k, 20 μg/
mL) during 48 to 96 hours or of IgE and anti-IgE as described
[22,23]. Cells may then be analyzed for their NOx (nitrite/
nitrate) content (see below) and cell supernatants for the pres-
ence of various inflammatory mediators. To detect cell apopto-
sis, externalization of inner membrane phosphatidylserine and
DNA content was investigated by flow cytometry using a fluo-
rescein-conjugated annexin V and propidium iodide kit (Immu-
notech, Marseille, France).
RNA preparations and transcriptomic arrays
After cultures, total RNA was extracted using Trizol (Invitrogen,
Cergy Pontoise, France) and was subsequently purified on
RNeasy columns (Qiagen, Hilden, Germany). Synthesis of
biotin-labelled cRNA, purification, and hybridization (6 μg) to
custom array membranes were performed according to the
manufacturer's recommendations (OHS-011; SuperArray
Bioscience Corporation, Frederick, MD, USA). For detailed
gene content and housekeeping controls, see reference [24].
After local background subtraction, average signal intensity
from duplicate spots was compared with values obtained for
housekeeping genes using Alpha Imager HP automatic image
capture software (Alpha-Innotec, San Leandro, CA, USA). For
each gene, modulation was defined as the relative expression
value for stimulated versus control sample.
Quantification of inflammatory mediators
For intracellular NO measurements, cells (>105) were incu-
bated with 10 μM DAF-FM-DA (4-amino-5-methylamino-2',7'-
difluoro-fluorescein diacetate; Molecular Probes, now part of
Invitrogen) for 1 hour at 37°C in 1 mL of culture medium. Cells
were then washed in PBS and incubated in 0.5 mL of PBS for
30 minutes at 37°C. Intracellular NO content was then inves-
tigated by flow cytometry. Cell supernatants (48 to 72 hours)
were assayed for the stable end product of NO, NO2
- using the
Griess reaction modified as detailed elsewhere [25]. The
inhibitory analog of L-arginine, N(6)-(1-iminoethyl)-L-lysine/
2HCl (L-NIL) (Coger SA, Paris, France) [26], was used to
inhibit inducible nitric oxide synthase (iNOS)-mediated NO
generation at a concentration of 1 mM. To detect human
cytokine levels, we have used a human multi-assay Th1/Th2 II
plex kit (Bender MedSystems, Vienna, Austria) and flow
cytometry. Inflammatory mediators in rat sera or cell superna-
tants were quantified using appropriate enzyme-linked immu-
nosorbent assay kits in accordance with the manufacturer's
recommendations for prostaglandin E2 (PGE2) (R&D Systems
Europe, Lille, France), monocyte chemoattractant protein-1
(MCP-1) (Tebu, Le Perray-en Yveline, France), TNF-α, and IL-
1β (Biosource, Montrouge, France).
Statistical analysis
Comparisons were assessed using the Fisher exact test for
proportions and the Mann-Whitney U test for quantitative val-
ues. A p value of less than 0.05 was considered significant.
For some rat in vitro experiments, results were analyzed and
compared using the Student t test for paired data.
Results
Inhibition of gene transcription in human macrophage by 
rutoside
In vitro, RU has generally been shown to display its activities
at concentrations of 30 to 200 μM [19]. Prior to RU use, we
first tested its effect on human normal or PHA-mediated
cycling PBLs in vitro. We had no significant increase of the
number of apoptotic (annexin+) or necrotic (propidium iodide+)
cells after 96 hours of cell incubation in the presence of 1 to
200 μM RU (range from -5% to +7% of cells). RU was then
used at concentrations of less than or equal to 100 μM in the
following experiments. After their separation, human mono-
cyte-derived macrophages were activated in the presence of
100 μM RU. The transcription of inflammatory genes was then
analyzed using a macrophage-specific macroarray. Compared
with resting cells, activated macrophages acquire a significant
expression of 20 new mRNAs encoding various inflammatory
mediators, chemotactic factors, and their receptors (Figure 1).
In addition, we observed a significant increase in mRNA
expression for genes encoding IL-1β, IL-8, TNF-α, TNF-R1,
and macrophage migration inhibitory factor (MIF) (>110%; p
< 0.05), known for their critical role during inflammatory
response [2,27]. Treatment of macrophages with RU inhibited
the expression of most of the above genes (19/20 were totallyArthritis Research & Therapy    Vol 10 No 1    Kauss et al.
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suppressed), including IL-1β, TNF-α, TNF-R1, and many che-
moattracting factors, or decreased the expression of genes
such as MIF and IL-8 (p < 0.05) (Figure 1). Surprisingly, the
transcription of the gene encoding IL-10, known as Th2 type
cytokine, was significantly increased (>230%; p  < 0.05).
These findings indicate that RU is a potent inhibitor of the tran-
scription of proinflammatory genes in human macrophages
with the exception of that encoding IL-10.
Rutoside modulates the generation of inflammatory 
mediators from activated macrophages
Transcriptomic data led us to investigate the effect of RU on
cytokine production at the protein level. Quantification of vari-
ous cytokines in macrophage cell supernatants indicates that
the addition of RU to human activated macrophages signifi-
cantly (p < 0.02) decreased the concentrations of TNF-α, IL-
1β, and IL-6 (Figure 2a), three critical proinflammatory
cytokines. We failed to detect significant modulation of IL-10
levels in contrast to mRNA data (Figures 1b and 2a).
In addition to the above cytokines, inflammatory macrophages
produce various non-proteic mediators, including iNOS-
dependent NO [22]. Upon their activation, human macro-
phages produce NO, detected at the intracellular level by spe-
cific probe (DF-FM) and at the extracellular level through the
quantification of nitrites, the final metabolites of NO in cell
supernatants. Data in Figure 2b show that RU partly inhibited
NO generation in a dose-dependent manner at both the intra-
cellular and extracellular levels. Generation of NO from human
macrophages was also reversed by L-NIL (Figure 2b), a spe-
cific inhibitor of iNOS [26], suggesting the ability of RU to
reverse iNOS-mediated NO production.
Rutoside decreases and prevents arthritic signs in rats
In vitro observations in human cells led us to investigate the
therapeutic anti-inflammatory effect of RU in vivo in rat AIA, an
experimental model with many clinical and histopathological
features of chronic human RA [28]. RU formulations and
doses used in this work were based upon various in vivo stud-
ies [29] and our preliminary analysis showing the absence of
an apparent toxic effect of up to 3,000 mg/kg total doses (data
not shown). AIA Lewis rats thus were treated with RU suspen-
sion at 133 mg/kg s.c. doses (one dose every 2 days × 5). As
therapeutic positive control, rats were treated with HC at 150
mg/kg total dose [30]. We found that administering five doses
of RU, beginning the day after the appearance of the first
arthritic symptoms, significantly improved the clinical course,
including arthritic scores and weight progression of AIA rats
as compared with the control groups (Figure 3a; p < 0.0001).
The effect of RU was superior to that of HC in inhibiting
arthritic scores (p < 0.001) and remained stable after treat-
ment (Figure 3a). Figure 3b shows the external aspect of
inflamed pads in RU-treated rats compared with untreated
rats. No obvious toxicity was observed resulting from the treat-
ment in the rats (for example, the weight of the treated normal
rats was close to untreated controls). Hence, these experi-
ments indicate that the RU effectively ameliorates AIA.
In a second set of experiments, we tested the ability of RU to
prevent AIA establishment in rats. We injected RU every 2
days for a total of five injections, beginning on the day of adju-
vant injection to the rats and before the appearance of any
arthritic signs. Notably, we found that pretreatment with RU
could significantly reduce the severity of arthritis and growth
delay observed in control groups (Figure 3c; p < 0.0002).
Hence, as shown in Figure 3d, RU treatment was effective
either at disease onset or prevention of severe disease estab-
lishment, whereas no such activity was obtained with controls.
Figure 1
Rutoside (RU) mediates the inhibition of inflammatory gene transcrip- tion in activated human macrophages Rutoside (RU) mediates the inhibition of inflammatory gene transcrip-
tion in activated human macrophages. Human monocyte-derived mac-
rophages were activated (10 μg/mL CD23-McAb) alone or in the 
presence of 100 μM RU. After 24 hours of incubation, cellular mRNAs 
were extracted and analyzed by inflammation-specific macroarray. (a) 
RU inhibits gene expression by activated human macrophages, with the 
exception of interleukin (IL)-10. A representative array from two distinct 
experiments is shown. (b) Inflammatory genes detected on each mem-
brane, in addition to controls. MIF, macrophage migration inhibitory fac-
tor; TNF, tumor necrosis factor.Available online http://arthritis-research.com/content/10/1/R19
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Rutoside and rat macrophage inflammatory mediators 
ex vivo
To confirm the anti-inflammatory effects of RU and the role of
macrophages, we tested the levels of selected mediators in
the sera from AIA animals following their treatment with or
without RU. Data (Figure 4a) show that RU significantly
reduced the levels of TNF-α, IL-1β, and MCP-1 in animal sera
(p < 0.02), whereas the level of PGE2, an indirect marker of
COX-2 (cyclooxygenase-2) activity, was not affected by this
treatment. These data reinforced human findings as they
revealed that RU decreased the level of inflammatory
cytokines, critical for RA pathogenesis in vivo. Although
known as a major source of the above mediators [2], the role
of macrophages during RU treatment required more direct ex
vivo analysis. Peritoneal macrophages were then isolated from
RU-treated or untreated arthritic rats and promptly incubated
in medium alone. After 48 hours of incubation, cell superna-
tants were analyzed for the levels of TNF-α and nitrites as
inflammatory markers. Our results (Figure 4b) clearly show
that increased inflammatory macrophage-derived TNF-α and
NO in AIA rats were attenuated after treatment with RU.
Finally, we tested the ability of RU to reduce rat macrophage
inflammatory responses in vitro. Peritoneal macrophages were
isolated from healthy rats and activated without various doses
of RU. Our data show (Figure 4d) that the levels of NO, as indi-
cated by the concentration of nitrites in cell supernatants,
decreased after the addition of RU in a dose-dependent man-
ner (p < 0.006). As in human cells, L-NIL had a similar inhibi-
tory effect compared with RU, suggesting its ability to
downregulate iNOS-mediated NO generation in macro-
phages. Inhibition reached a plateau at 50 μM RU, a concen-
tration that was subsequently used to investigate the RU effect
on other mediators. As in in vivo findings, RU decreased the
level of inflammatory cytokines (TNF-α, IL-1β, and MCP-1)
generated from activated rat macrophages (Figure 4c). As in
ex vivo data, the production of PGE2 was not modified after
the addition of similar RU dilution.
Discussion
Macrophages arise as an interesting target for modulation of
inflammatory disease. Inflammatory mediators derived from
these cells have a critical role during synovial inflammation and
bone destruction in some patients with RA [7,8]. Obtained
using various approaches, our results clearly indicate that RU,
a molecule already used in vascular diseases, inhibited the
activation of human macrophages and the subsequent secre-
tion of proinflammatory mediators from these cells. RU was
shown to inhibit the transcription of more than 20 genes
encoding critical proinflammatory factors, including TNF-α, IL-
1, IL-8, TNF-α, MIF, and chemoattracting factors. This effect
was confirmed by decreased concentrations of IL-1β, TNF-α,
and IL-6 observed in cell supernatants.
Figure 2
Inhibition of inflammatory mediator generation from activated human  macrophages Inhibition of inflammatory mediator generation from activated human 
macrophages. (a) Rutoside (RU) decreased the generation of tumor 
necrosis factor-alpha (TNF-α), interleukin (IL)-1β, and IL-6 but not IL-10 
from activated human macrophages. (b) Inhibition of nitric oxide (NO) 
generation from human activated macrophages after their incubation 
with various RU concentrations. RU decreases both intracellular NO 
(upper panel) and extracellular nitrites (lower panel). Specific inducible 
nitric oxide synthase inhibitor (L-NIL, 1 mM) was used as control. 
Results from three different cell preparations ± standard deviation are 
shown. *P value obtained as compared to activated cells. L-NIL, N(6)-
(1-iminoethyl)-L-lysine/2HCl.Arthritis Research & Therapy    Vol 10 No 1    Kauss et al.
Page 6 of 9
(page number not for citation purposes)
NO has been identified as another proinflammatory mediator
in human arthritis and experimental animal studies [3,31].
Increased concentrations of nitrites, stable metabolites of NO,
have been observed in the serum and the synovial fluid of
patients with RA and osteoarthritis [3,32]. Increased iNOS
activity and NO production have also been detected in the
blood mononuclear cells of patients with RA and correlated
with the tender and swollen joint counts [33]. Here, we show
that RU decreased the production of iNOS-mediated NO by
human macrophages in a dose-dependent manner. Of partic-
ular interest, and by contrast to the above mediators, RU
induced a slight but significant increase of IL-10 mRNA. How-
ever, we failed to detect an increase of IL-10 protein level. This
may be due to the absorption of IL-10 by macrophages, as yet
observed in CD23-activated human epithelial cells [34]. This
Th2 type cytokine is well known as a downregulator of the
above-mentioned Th1 mediators in human macrophages [35].
These preliminary data suggest that RU preferentially lowers
Th1-like cytokine generation from human macrophages.
To support the therapeutic interest of RU, we investigated its
effects in a rat model of adjuvant-induced chronic arthritis, well
known to mimic Th1 type pathogenic signs of RA [28]. RU sig-
nificantly reversed growth delay and severe AIA development
in rats with persistent partial or complete long-term recovery,
not observed in rats treated with HC. These data confirm early
observations in experimental acute inflammation models [18-
20,36] and further revealed the preventive property of RU in
arthritic rats. Ex vivo analysis of rat sera and macrophages
confirmed RU-mediated inhibition of critical proarthritic factors
such as TNF-α, IL-1, MCP-1, and NO in vivo. This property
correlated with RU-mediated inhibition of murine macrophage
Figure 3
The evolution of arthritis severity scores of adjuvant-induced arthritis (AIA) in rats following their treatment with rutoside (RU) The evolution of arthritis severity scores of adjuvant-induced arthritis (AIA) in rats following their treatment with rutoside (RU). (a) Arthritis clinical 
scores (upper panel) and body weight (lower panel) of young AIA rats following their treatment with 133 mg/kg subcutaneous doses of RU suspen-
sion, every 2 days × 5, as indicated by arrows starting after the appearance of clinical symptoms. As positive control, AIA rats received five injections 
of 30 mg/kg hydrocortisone (HC). Results are means from five rats from each group (standard deviation [SD] less than 25% for all groups). (b) 
External aspects of rat paws showing swelling (left), swelling + immobility (central), and healed paws following RU treatment (right). (c) Amelioration 
of arthritis severity scores (upper panel) and body weight (lower panel) of AIA rats following preventive treatment with 5 × 133 mg/kg doses of RU 
suspension, starting the first day of immunization, before AIA development. Results are means from five rats (SD less than 25% for all groups). (d) 
Cumulative AIA clinical scores from untreated rats, hydrocortisone (HC)-treated rats, or those treated by RU prior to AIA development (Pre-AIA) or 
following arthritis development (Post-AIA). Bars represents cumulative AIA severity scores over the course of 40 days of observation (days 0 to 40) 
of five rats from each group. *P value compared to untreated AIA rats.Available online http://arthritis-research.com/content/10/1/R19
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activation and inflammatory mediator release in vitro (Figures
3 and 4). In contrast to quercetin [37], RU did not mediate the
inhibition of the PGE2 pathway.
Together, the above data provide new insight into the possible
mechanism of anti-inflammatory effects of RU in macrophages.
Human and murine analyses of cytokine expression clearly
show that RU suppresses the major inflammatory and proar-
thritic mediators of macrophages. The ability of RU to
decrease MCP-1 levels in vivo and in vitro may add to its ben-
eficial effects because this cytokine is a potent stimulator of
monocyte recruitment into the site of inflammation [38]. We
have previously shown that the nonglycosylated derivative of
RU, quercetin, inhibits the production of TNF-α and NO from
activated human macrophages [39]. These flavonols inhibit
the phosphorylation and activation of Jun N-terminal kinase/
stress-activated protein kinase, leading to the suppression of
AP-1 activation. They also decrease the activation of NF-κB in
both human and experimental models [12,40]. These observa-
tions may explain the anti-inflammatory property of RU
because both nuclear factors are necessary for the generation
of most inflammatory mediators analyzed in the present study
[41-43].
However, the exact mechanism underlying the improvement in
the arthritis model requires more experimental clarifications.
Despite the direct relationship between arthritis signs and
macrophage inflammatory markers in the AIA rat model, we
must not exclude the simultaneous effect of RU on other
inflammatory partners (such as lymphocytes) that may directly
or indirectly reduce arthritis manifestations. In addition, AIA is
a good model for Th1-mediated and macrophage inflammatory
response but is a poor model for Th2-mediated immune reac-
tions. Further analysis of RU activities in the presence of vari-
Figure 4
Effect of rutoside (RU) treatment on rat inflammatory mediators Effect of rutoside (RU) treatment on rat inflammatory mediators. (a) Sera were collected at day 50 after immunization and tested for their concentra-
tions in tumor necrosis factor-alpha (TNF-α), prostaglandin E2 (PGE2), interleukin-1-beta (IL-1β), and monocyte chemoattractant protein-1 (MCP-1). 
Results are shown as mean percentage of modulation of cytokine levels compared to healthy rats. Mean percentage + standard deviation from three 
rats in each group is shown. P value compared to untreated adjuvant-induced arthritis (AIA) rats. (b) Freshly isolated peritoneal macrophages from 
untreated or RU-treated rats were collected on day 50 after immunization. They were incubated in medium alone during 48 hours, and their superna-
tants were collected and tested for their TNF-α or nitrite levels. P value compared to untreated AIA rat cells. (c) Macrophages from normal rats were 
incubated in medium alone or activated by lipopolysaccharide. RU was added (50 μM) simultaneously to cell activation. Cell supernatants were har-
vested 48 hours after incubation and tested for their concentrations of TNF-α, PGE2, IL-1β, and MCP-1. P value compared to activated cells. (d) RU 
inhibits the release of nitric oxide from activated rat macrophages in a dose-dependent manner. Bars show mean + standard deviation from three dif-
ferent rat cell preparations. P value compared to activated cells.Arthritis Research & Therapy    Vol 10 No 1    Kauss et al.
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ous human lymphocyte populations is required to clarify these
points.
Finally, in vivo use of quercetin as medicine suffers from the
lack of approved formulation despite a first preliminary assay
as adjunct treatment of prostatitis/chronic pelvic pain in
humans [44]. In contrast, formulations containing either RU or
its derivatives are currently used in the treatment and preven-
tion of venous circulation disorders [11,45].
Conclusion
RU appears as an interesting cost-effective therapeutic tool in
inflammatory diseases and represents an alternative to immu-
nosuppressor agents well known for their multiple side effects.
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